Quarterly report pursuant to Section 13 or 15(d)

RELATED PARTY TRANSACTIONS (Details Narrative)

v3.22.1
RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended 12 Months Ended
Jan. 31, 2021
Mar. 31, 2022
Mar. 31, 2021
Dec. 31, 2020
Dec. 31, 2021
Legal Fees   $ 0 $ 37,551    
Accounts Payable and Accrued Liabilities   397,909     $ 195,000
Series B Preferred Stock [Member]          
Debt Conversion, Original Debt, Amount $ 156,000        
Short-term Notes Payable [Member]          
Proceeds from Short-Term Debt       $ 45,500  
Debt Instrument, Interest Rate During Period       10.00%  
Short-Term Debt   7,500      
Short-term Notes Payable [Member] | Series B Preferred Stock [Member]          
Debt Conversion, Original Debt, Amount   $ 23,000      
Debt Conversion, Converted Instrument, Shares Issued   23      
Class of Warrant or Right, Number of Securities Called by Warrants or Rights   1,643      
Class of Warrant or Right, Exercise Price of Warrants or Rights   $ 14.00      
President [Member]          
Officers compensation   $ 500      
Officers and Directors [Member] | Series B Preferred Stock [Member]          
Debt Instrument, Convertible, Conversion Price   $ 1,000      
IGL Pharma Inc [Member] | President [Member]          
Non-controlling interest percentage   1.00%